ProfileGDS5678 / 1436515_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 57% 57% 57% 57% 54% 60% 56% 69% 55% 58% 57% 56% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3992954
GSM967853U87-EV human glioblastoma xenograft - Control 23.4576157
GSM967854U87-EV human glioblastoma xenograft - Control 33.4609757
GSM967855U87-EV human glioblastoma xenograft - Control 43.4181657
GSM967856U87-EV human glioblastoma xenograft - Control 53.4000757
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4215254
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6573460
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4082156
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2824769
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3390855
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4849458
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4244857
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.433756
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4392657